A large trial of low-dose amitriptyline resulted in nearly twice as many people reporting symptom relief for IBS as placebo, with researchers suggesting that GPs should be offer the drug more often.
Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a "once in a career" result, study authors say.
An updated meta-analysis found some evidence that certain probiotics may improve symptoms in irritable bowel syndrome, but the certainty of evidence was low across nearly all analyses.